Press releases

GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)

Geneva, Switzerland, June 25, 2020 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), today announces the inclusion of the first patient in its Phase 2 trial of temelimab in MS at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, Sweden.

https://geneuro.ch/data/news/2020.06.25-GeNeuro-MSResumption-EN-VF.pdf

GeNeuro Announces the Approval of all Resolutions proposed at the AGM

Geneva, Switzerland, May 28, 2020 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2020.

https://geneuro.ch/data/news/2020.05.28-GeNeuro-AGM-28052020-ENG.pdf

GeNeuro: financial information and business update for the first quarter 2020

Geneva, Switzerland, April 27, 2020 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2020 first quarter cash position and issued a business update.

https://geneuro.ch/data/news/GeNeuro-PR-Q1-2020-EN.pdf

GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

Geneva, Switzerland, April 21, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis , today announces the appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.

https://geneuro.ch/data/news/GeNeuro-PR-CMO-appointment-EN.pdf

GeNeuro Reports 2019 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 7, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today reported its full-year results for the year ended December 31, 2019 and provided a corporate update

https://geneuro.ch/data/news/GeNeuro-PR-FYR2019results.pdf

GeNeuro Phase 2 multiple sclerosis trial update

Geneva, Switzerland, March 19, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced the temporary postponement of its planned Phase 2 trial of temelimab in multiple sclerosis (MS) at the Karolinska Institutet’s Academic Specialist Center (ASC), Stockholm, Sweden, to prioritize healthcare resources behind the fight of COVID-19 and to reduce the risk for MS patients.

https://geneuro.ch/data/news/GeNeuro-PR-TemelimabCOVID19-EN.pdf